The 2014 outbreak clearly showed that Ebola viruses (EBOV) remain a substantial 
threat for public health. The mainstay of management of patients with Ebola 
disease is isolation of patients and use of strict barrier nursing procedures; 
the present treatment strategies are mainly symptomatic and supportive (fluid 
resuscitation, antypyretics, antidiarrheal drugs). Currently, there is no 
approved therapy for Ebola hemorrhagic fever (EHF), however several advanced 
treatment options were tested in animal models (on non-human primates or 
rodents). They include use of both symptomatic (e.g. use of tissue factor 
inhibitors - rhNAPc2, rhAPC - to abolish coagulopathy) and specific antiviral 
approaches: e.g. monoclonal anti EBOV antibodies (ZMapp, MB-003), 
phosphorodiamidate morpholino oligomers (PMOs), liposomes containing siRNA 
(LNP-siRNA:TKM-Ebola) and small molecule inhibitors (e.g. BCX4430, favipiravir). 
The scope of this article is to briefly review the most promising therapeutics 
for EHF, based on the data coming from rare clinical reports, studies on animals 
and results from in vitro models.